Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

CCJ

Unveiling Cameco – A Quick Overview

Cameco shares fell by -1.4% during the day's morning session, and are now trading at a price of $105.4. Is it time to buy the dip? To better answer that question, it's essential to check if the market is valuing the company's shares fairly in terms of its earnings and equity levels.

Cameco's Valuation Is in Line With Its Sector Averages:

Cameco Corporation provides uranium for the generation of electricity. The company belongs to the Basic Materials sector, which has an average price to earnings (P/E) ratio of 20.25 and an average price to book (P/B) ratio of 2.31. In contrast, Cameco has a trailing 12 month P/E ratio of 119.8 and a P/B ratio of 6.81.

Cameco has moved 98.1% over the last year compared to 18.5% for the S&P 500 — a difference of 79.5%. Cameco has a 52 week high of $110.16 and a 52 week low of $35.0.

Wider Gross Margins Than the Industry Average of 21.0%:

2019 2020 2021 2022 2023 2024
Revenue (M) $1,863 $1,800 $1,475 $1,868 $2,588 $3,136
Gross Margins 13% 6% 0% 12% 22% 25%
Net Margins 4% -3% -7% 5% 14% 5%
Net Income (M) $74 -$53 -$103 $89 $361 $172
Net Interest Expense (M) $62 $66 $39 $39 $51 $85
Depreciation & Amort. (M) $276 $209 $190 $177 $220 $281
Earnings Per Share $0.19 -$0.13 -$0.26 $0.22 $0.83 $0.39
EPS Growth n/a -168.42% -100.0% 184.62% 277.27% -53.01%
Avg. Price $10.15 $9.82 $19.27 $24.15 $43.1 $106.91
P/E Ratio 53.42 -75.54 -74.12 109.77 51.93 267.27
Free Cash Flow (M) $527 $57 $458 $305 $688 $905
Total Debt (M) $997 $996 $996 $997 $1,284 $996
Net Debt / EBITDA -0.18 0.59 -4.63 -0.76 1.43 0.5
Current Ratio 6.51 6.4 5.18 5.92 1.55 1.62

Cameco benefits from generally positive cash flows, wider gross margins than its peer group, and a strong EPS growth trend. The company's financial statements show a decent current ratio of 1.62 and healthy leverage levels.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS